MA45690A - Anticorps anti-tgfb, méthodes et utilisations - Google Patents

Anticorps anti-tgfb, méthodes et utilisations

Info

Publication number
MA45690A
MA45690A MA045690A MA45690A MA45690A MA 45690 A MA45690 A MA 45690A MA 045690 A MA045690 A MA 045690A MA 45690 A MA45690 A MA 45690A MA 45690 A MA45690 A MA 45690A
Authority
MA
Morocco
Prior art keywords
methods
tgfb antibodies
tgfb
antibodies
Prior art date
Application number
MA045690A
Other languages
English (en)
Inventor
Gregory J Carven
Thomas Schurpf
Katherine Turner
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA45690A publication Critical patent/MA45690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045690A 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations MA45690A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05

Publications (1)

Publication Number Publication Date
MA45690A true MA45690A (fr) 2019-05-22

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045690A MA45690A (fr) 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations

Country Status (13)

Country Link
US (2) US20190292254A1 (fr)
EP (1) EP3484499A4 (fr)
JP (2) JP7128801B2 (fr)
KR (1) KR102577551B1 (fr)
CN (1) CN110049773A (fr)
AU (1) AU2017294772B2 (fr)
BR (1) BR112019000621A2 (fr)
CA (1) CA3030862A1 (fr)
IL (1) IL264161B2 (fr)
MA (1) MA45690A (fr)
MX (1) MX419976B (fr)
SG (1) SG11201900200XA (fr)
WO (1) WO2018013939A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
CA3055555A1 (fr) 2016-03-11 2017-09-14 Scholar Rock, Inc. Immunoglobulines se liant a tgfb1 et leur utilisation
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
US20210340238A1 (en) * 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
US20240190961A1 (en) * 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
TW202135862A (zh) * 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
EP4348260A2 (fr) 2021-06-03 2024-04-10 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
CN116547300B (zh) * 2021-09-30 2024-10-08 贝达药业股份有限公司 双特异性抗体及其应用
TW202434643A (zh) * 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
CN118829657A (zh) * 2023-02-06 2024-10-22 贝达药业股份有限公司 多特异性抗体及其应用
WO2024187051A1 (fr) 2023-03-07 2024-09-12 Scholar Rock, Inc. Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients
WO2025240343A1 (fr) 2024-05-13 2025-11-20 Scholar Rock, Inc. Inhibiteurs de tgf-bêta pour le traitement du cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011384A1 (fr) 1992-11-13 1994-05-26 Immunex Corporation Nouvelle cytokine appelee ligand d'elk
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0756627A1 (fr) 1994-04-15 1997-02-05 Amgen Inc. Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
AU779892B2 (en) 1999-08-27 2005-02-17 European Molecular Biology Laboratory Modified adenoviral fibre and uses thereof
NZ521437A (en) 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
EP2295081B1 (fr) 2001-06-26 2018-10-31 Amgen Inc. Anticorps OPGL
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
MX2008000985A (es) * 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN103003424B (zh) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
PL2904011T3 (pl) * 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
EP3139957A4 (fr) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions et procédés de modulation de facteur de croissance
WO2016164468A2 (fr) * 2015-04-07 2016-10-13 The Trustees Of The University Of Pennsylvania Autoanticorps monoclonaux humains contre adamts13 et leurs utilisations
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
CA3055555A1 (fr) * 2016-03-11 2017-09-14 Scholar Rock, Inc. Immunoglobulines se liant a tgfb1 et leur utilisation

Also Published As

Publication number Publication date
KR102577551B1 (ko) 2023-09-11
KR20190034560A (ko) 2019-04-02
SG11201900200XA (en) 2019-02-27
EP3484499A4 (fr) 2020-05-13
MX419976B (es) 2025-01-14
MX2019000514A (es) 2019-07-12
AU2017294772A1 (en) 2019-01-31
IL264161A (en) 2019-02-28
US20190292254A1 (en) 2019-09-26
JP7128801B2 (ja) 2022-08-31
AU2017294772B2 (en) 2024-05-02
WO2018013939A1 (fr) 2018-01-18
BR112019000621A2 (pt) 2019-04-24
JP2022153406A (ja) 2022-10-12
US20210277100A1 (en) 2021-09-09
CN110049773A (zh) 2019-07-23
US12281159B2 (en) 2025-04-22
EP3484499A1 (fr) 2019-05-22
IL264161B2 (en) 2025-06-01
JP2019524094A (ja) 2019-09-05
CA3030862A1 (fr) 2018-01-18
IL264161B1 (en) 2025-02-01

Similar Documents

Publication Publication Date Title
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
EP3658589C0 (fr) Anticorps anti-sirp-alpha et méthodes associées
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
EP3411412A4 (fr) Technologie fit-immunoglobuline et ses utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3400243A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA43814A (fr) Anticorps anti-gitr, méthodes et utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations